Executives from 4D Molecular Therapeutics (NASDAQ:FDMT) outlined the company’s gene therapy platform, clinical progress, and commercialization plans during a Barclays analyst discussion in Miami, ...

Ophthalmology is the highest volume outpatient specialty within the NHS and the medicines used for medical retinal vascular conditions account for some of the highest cost and volume treatments used ...

Ex-Pakistan Prime Minister Imran Khan is expected to be moved to a hospital in the coming days for further medical care, sources say. The move comes amid growing concerns over his health while he ...

As Korea transitions into a super-aged society, the prevalence of neovascular age-related macular degeneration (nAMD) is rising rapidly, establishing it as a leading cause of blindness and presenting ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...

TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...

TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...

The agency approved a monthly dosing option for select patients acorss all approved indications, including wAMD, DME, DR, and RVO. FDA approved aflibercept (Eylea HD) 8 mg for macular edema following ...